PurpleWin Promotes BioLife’s Virus-Reduced hPL to Help Cell Therapy Developers Meet Regulatory Deman
Exhibitor: PURPLE WIN INTERATIONAL LIMITED.
Date: 2025-06-12
Booth No.: L124
On May 2025, Taiwan’s Ministry of Health and Welfare (MOHW) announced a significant regulatory update for cell therapy. Starting in 2028, all cell therapy applications—including new submissions, amendments, and extensions—must include documented proof of reagent quality along with viral inactivation or clearance validation data. Applications failing to meet these criteria will not be approved. The announcement clearly states that any reagent derived from human or animal sources must be accompanied by risk assessments for potential pathogens and evidence of effective viral inactivation or control measures.
Industry Solution: BioLife’s Virus-Reduced hPL Products – nLiven and TLiven
In response to this regulatory shift, PurpleWin Industrial Co., Ltd. strongly recommends BioLife's virus-reduced human platelet lysate (hPL) products, nLiven and TLiven, developed in the United States. These products utilize proprietary E-beam (electron beam) irradiation technology, offering highly effective pathogen inactivation with deep penetration and low-temperature processing, ensuring protein stability and functionality.
nLiven and TLiven come with comprehensive supporting documentation, including an active Drug Master File (DMF) with the FDA and PMDA applicability documentation in Japan. These products are suitable for clinical use in Taiwan, the U.S., EU, and other regulated markets. With full traceability, quality certification, and virus inactivation performance data, BioLife has become the preferred partner for cell therapy developers navigating evolving compliance requirements.
For more information or technical support, please contact PurpleWin Industrial at +886-2-7720-1566.
More Exhibitor's Press Release
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-19
- GlobalBio: 國鼎生技-開發Antroquinonol 造福抗癌研究治療 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-19
- From GMP Cell Sorting to Real-Time Drug Response Analysis: A Preview of Cell-Bio's Technology Showca CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-18
- Focusing on dementia and brain health APN LIFESCIENCES INC / 2025-07-16
- Conquering the Final Hurdle of Cell Therapy Commercialization: Sony Senior Manager to Share Exclusiv CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-16
- Indiana - America's Life Sciences Powerhouse INDIANA ECONOMIC DEVELOPMENT CORPORATION, TAIWAN OFFICE / 2025-07-16
- Urine-Based Cancer Testing: Vitae Biomedical Pioneers a Non-Invasive Path to Lung Cancer Detection VITAE BIOMEDICAL CO. LTD. / 2025-07-16
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-15
- MabPlex : ONE-STOP CDMO FOR BIOPHARMACEUTICALS MABPLEX INTERNATIONAL CO., LTD. / 2025-07-15
- Next Generations Therapy Manufacturing LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- The Fastest and Safest Depth Filtration LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- Highest Cell Viability in Perfusion LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- Accelerate Your Exosome Development Timeline: Cell Bio to Unveil Key Analytical Technologies CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-14
- LiZhong Pathology Laboratory Achieves ISO/IEC 17025 Accreditation, Reaching International Standards BIOTNA, INC. / 2025-07-14
- VP-Motion is Japan’s leading AI-powered human behavior analysis software JYTC CO., LTD. / 2025-07-13
- Igus and JYTC walk together for better options. (German beer limited served daily) JYTC CO., LTD. / 2025-07-13
- Why choose Mecademic for robotic lab automation? JYTC CO., LTD. / 2025-07-13
- National Yang Ming Chiao Tung University’s Innovative Biotech and Medical Technologies NATIONAL YANG MING CHIAO TUNG UNIVERSITY / 2025-07-11
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-09
- Rooted in Mountains, Climbing the Peaks. BIOMEDICAL TRANSLATION RESEARCH CENTER, ACADEMIA SINICA (NATIONAL BIOTECHNOLOGY RESEARCH PARK) / 2025-07-09